Center-Authored Papers

Filters: Author is Thorpe, Jason D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW et al..  2008.  Systematic evaluation of candidate blood markers for detecting ovarian cancer.. PloS one. 3(7):e2633. Abstract
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
2009
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Pitteri SJ, JeBailey L, Faça VM, Thorpe JD, Silva MA, Ireton RC, Horton MB, Wang H, Pruitt LC, Zhang Q et al..  2009.  Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.. PloS one. 4(11):e7916. Abstract
2010
Anderson GL, McIntosh MW, Wu LL, Barnett M, Goodman GE, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N et al..  2010.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38. Abstract
2011
Urban ND, Thorpe JD, Bergan LA, Forrest RM, Kampani AV, Scholler N, O'Briant KC, Anderson GL, Cramer DW, Berg CD et al..  2011.  Potential Role of HE4 in Multimodal Screening for Epithelial Ovarian Cancer.. Journal of the National Cancer Institute. 103(21):1630-4. Abstract
2014
Miller CP, Thorpe JD, Kortum AN, Coy CM, Cheng W-Y, Ou Yang T-H, Anastassiou D, Beatty JD, Urban ND, Blau AC.  2014.  JAK2 Expression Is Associated with Tumor-Infiltrating Lymphocytes and Improved Breast Cancer Outcomes: Implications for Evaluating JAK2 Inhibitors.. Cancer immunology research. 2(4):301-6. Abstract
Karlan BY, Thorpe JD, Watabayashi K, Drescher CW, Palomares MR, Daly M, Paley PJ, Hillard PJ, Andersen MR, Anderson GL et al..  2014.  Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
Adult
Anderson GL, McIntosh MW, Wu LL, Barnett M, Goodman GE, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N et al..  2010.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38. Abstract
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Aged
Anderson GL, McIntosh MW, Wu LL, Barnett M, Goodman GE, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N et al..  2010.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38. Abstract
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Aged, 80 and over
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Animals
Pitteri SJ, JeBailey L, Faça VM, Thorpe JD, Silva MA, Ireton RC, Horton MB, Wang H, Pruitt LC, Zhang Q et al..  2009.  Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.. PloS one. 4(11):e7916. Abstract
Antibodies
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Antibodies, Monoclonal
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
Antigens, CD80
Anderson GL, McIntosh MW, Wu LL, Barnett M, Goodman GE, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N et al..  2010.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38. Abstract
Area Under Curve
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Anderson GL, McIntosh MW, Wu LL, Barnett M, Goodman GE, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N et al..  2010.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38. Abstract
BIOTINYLATION
Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R et al..  2008.  Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(9):2647-55. Abstract
CA-125 Antigen
Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, Andersen MR, Scholler N, Bergan LA, Thorpe JD et al..  2009.  Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72. Abstract
Anderson GL, McIntosh MW, Wu LL, Barnett M, Goodman GE, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N et al..  2010.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38. Abstract
Case-Control Studies
Anderson GL, McIntosh MW, Wu LL, Barnett M, Goodman GE, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N et al..  2010.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.. Journal of the National Cancer Institute. 102(1):26-38. Abstract